Canwell Biotech Ltd. has described tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer.
Canwell Biotech Ltd. has described antibody-drug conjugates (ADCs) comprising an antibody covalently linked to a Toll-like receptor 7 (TLR7) and TLR8 agonist through a cleavable or noncleavable linker reported to be useful for the treatment of cancer, allergy, autoimmune diseases, immunodeficiency disorder, sepsis and infections.
Researchers from Canwell Biotech Ltd. presented preclinical data for CAN-2109, a novel long-acting immunogenic cell death inducer being developed for the treatment of cancer.
A recent Canwell Biotech Ltd. patent details the discovery of methionine aminopeptidase-2 (MetAP2) inhibitors reported to be useful for the treatment of cancer, diabetes, obesity, rheumatoid arthritis and psoriasis.
Canwell Biotech Ltd. raised more than ¥100 million (US$14.8 million) in a series A+ financing. The funds will help accelerate trials for its pipeline of anticancer assets, such as the TLR7 agonist CAN-1012, and preclinical development of other projects too, CEO Henry Yu told BioWorld. The State Development and Investment Corporation Venture Capital Co. Ltd. was the round’s sole investor.
